Molecular Basis of the Dystrophic and Junctional Forms of Epidermolysis Bullosa: Mutations in the Type VII Collagen and Kalinin (Laminin 5) Genes  by Uitto, Jouni et al.
Molecular Basis of the Dystrophic and Junctional 
Forms of Epidermolysis Bullosa: Mutations in the 
Type VII Collagen and Kalinin (Laminin 5) Genes 
Jouni Uitto, Leena Pulkkinen, and Angela M. Christiano 
Departments of Dermatology, and Biochemistry and Molecular Biology, Jefferson Medical College; and Section of Molecular 
Dennatology, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, U.S.A. 
Epidermolysis bullosa (EB) is a group of heritable me­
chano-bullous skin diseases classified into three major 
categories, the simplex, junctional, and dystrophic 
forms, on the basis of the level of tissue separation 
within the dermal-epidermal basement membrane 
zone. Approaches of molecular biology have demon­
strated that these three different forms of EB result 
from mutations in distinct genes: the simplex forms 
are due to mutations in the genes encoding keratins 5 
and 14 expressed in basal keratinocytes; the junctional 
forms are associated with mutations in the kalinin/la­
moon 5 genes; and the dystrophic forms result from 
mutations in the type VB collagen gene (COL 7 A1). In 
this overview, we summarize our recent discoveries of 
E pidermolysis bullosa (EB) is a group of genodermatoses characterized by fragility and easy blistering of the skin and the mucous membranes [1,2]. On the basis of clini­cal, morphologic, and ultrastructural observations, EB can be divided into three major categories. In the sim­
plex (non-scarring) forms, tissue separation takes place at the level 
of basal keratinocytes, and mutations in the keratin genes (KRT5 
and KRT14), expressed in the basal cells, have been shown to un­
derlie this form ofEB [3,4]. In the junctional forms ofEB (JEB), the 
tissue separation occurs within the dermal-epidermal basement 
membrane at the level of the lamina lucida, and the anchoring 
filament proteins, nicein/kalinin/laminin 5 (which all refer to the 
same protein) [5] or epiligrin (which may be a closely related protein 
complex) [6], have been implicated as the candidate genes. In the 
dystrophic forms of EB (DEB), the tissue separation occurs below 
the basement membrane within the papillary dermis at the level of 
the anchoring fibrils, which are either quantitatively or qualita­
tively abnormal, as determined by electron microscopy [7]. Because 
anchoring fibrils are comprised of type VII collagen [8], the corre­
sponding gene (COL7 Al) was initially proposed to harbor the mu­
tation in DEB. Both autosomal dominant and autosomal recessive 
inheritance patterns have been documented, and the blistering 
tendency can be highly variable within different forms ofEB [1,2]. 
Leena Pulkkinen is on leave of absence from the Department of Obstetrics 
and Gynecology, Division of Medical Genetics, Kuopio University Central 
Hospital, Finland. 
Reprint requests to: Dr. Jouni Uitto, Depattment ofDermatology,Jeffer­
son Medical College, 233 South 10th Street, Room 450, Philadelphia, PA 
19107. 
pathogenic mutations in COL7A1, including prema­
ture termination codons that result in the severe, muti­
lating (Hallopeau-Siemens) type of recessive dystro­
phic EB and a glycine substitution in the collagenous 
region resulting in dominant dystrophic EB. Further­
more, we present evidence that implicates mutations 
in the kalinin/laminin 5 1'2 chain gene (LAMC2) in 
some forms of junctional EB. This information has 
provided the basis for DNA-based prenatal diagnosis 
during the first trimester of gestation, and sets the stage 
for the application of gene therapy to these devastating 
skin diseases in the future.] I"vest Dermatol10J:39S-
46S, 1994 
STRUCTURAL FEATURES OF THE CUTANEOUS 
BASEMENT MEMBRANE ZONE 
The dermal-epidermal basement membrane zone, by analogy to 
other stratifying squamous epithelia, such as the mucous mem­
branes and the cornea of the eye, contain specialized attachment 
structures that are thought to play a critical role in stabilizing the 
association of the epidermis and dermis [9]. These attachment struc­
tures include hemidesmosomes that are known to consist of at least 
three different proteins, including the 230-kDa bullous pemphi­
goid antigen (BPAG1), the 180-kDa bullous pemphigoid antigen 
(BPAG2 or type XVII collagen), and the a6p4 integrin [10]. The 
hemidesmosomes extend from the intracellular compartment of the 
basal keratinocytes into the extracellular milieu where they asso­
ciate with the lamina lucida. 
Within the lamina lucida, fibrillar structures, known as anchor­
ing filaments, can be recognized by transmission electron micros­
copy. Based on immunoelectron microscopy, the anchoring fila­
ments were initially shown to consist of a protein known as 
nicein/kalinin, a heterotrimeric molecule with homology to la­
minin, a ubiquitous multifunctional basement membrane protein 
[11]. Similar to laminin, nicein/kalinin was shown to consist of 
three distinct subunits, designated as the A, B 1, and B2 chains (5). In 
fact, due to homology of the individual chains of nicein/kalinin 
with the corresponding chains of laminin or other laminin-like 
molecules, a new nomenclature has recently been proposed that 
designates nicein/kalinin as laminin 5 (see [5] and below). 
On the dermal side of the cutaneous basement membrane zone, 
attachment structures known as anchoring fibrils are observed. 
These fibril structures extend from the lamina densa on the lower 
part of the cutaneous basement membrane zone to the upper papil-
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lary dermis where the other end of the anchoring fibrils associates 
with basement membrane-like structures, known as anchoring 
plaques [8,9]. The anchoring fibrils consist of type VII collagen, and 
during extracellular assembly, individual type VII collagen mole­
cules form anti-parallel dimers that associate through their overlap­
ping carboxy-terminal ends. This association is then stabilized by 
the formation of intermolecular disulfide bonds [8]. Subsequently, 
numerous dimer molecules laterally assemble to form the anchoring 
fibrils, recognizable in electron microscopy (EM) by their charac­
teristic banding pattern, which contain large amino-terminal glob­
ular domains at both ends of the fibrils. Recent cloning of type VII 
collagen has facilitated elucidation of the entire primary amino acid 
sequence of the al(VlI) chains, as deduced from the full-length 
cDNA [12-15]. These analyses have disclosed that the central col­
lagenous domain, -145 kDa in size, consists of repeating Gly-X-Y 
sequence that is interrupted 19 times by imperfections or non-col­
lagenous interruptions. The central collagenous segment is flanked 
by non-collagenous end domains. The larger, -145-kDa, arnino­
terminal non-collagenous (NC-l) domain of the al(VlI) chain 
consists of submodules with homology to known adhesive proteins 
[13,14]. These include segments with homology to cartilage matrix 
protein, nine consecutive fibronectin type III (FNIII)-like domains, 
and a segment with homology to the A domain of von Willebrand 
factor. The carboxy-terminal non-collagenous (NC-2) end is rela­
tively small, -17 kDa, and contains a segment with homology to 
the Kunitz protease inhibitor [15]. Thus, type VII collagen is com­
prised of different domains that appear to be necessary for the for­
mation of functional anchoring fibrils. 
MOLECULAR GENETICS OF EPIDERMOLYSIS BULLOSA 
Recent studies have clearly established that the simplex forms ofEB, 
usually inherited in a dominant manner, are due to mutations in the 
genes encoding the basal keratins, S and 14 [3,4]. Most of these 
mutations are single base substitutions that result in the formation of 
a perturbed keratin intermediate filament network by a dominant 
negative mechanism. As a result, the basal keratinocytes are fragile, 
and minor trauma to the skin leads to cytolysis and blister formation 
just above the basement membrane. The consequences of these sin­
gle base substitutions have also been verified through the generation 
of transgenic animals that similarly demonstrate blister formation at 
the level of the basal keratinocytes [16]. Furthermore, in vitro recon­
stitution of the mutated keratin filaments containing the amino acid 
substitutions have unequivocally demonstrated the role of these 
mutations as the cause of the tissue fragility in the simplex forms of 
EB [16,17]. In addition to missense mutations, a three-bp deletion 
has also recently been demonstrated in a family with dominantly 
inherited EB simplex [18]. In addition, a homozygous missense 
mutation has been identified in a recessively inherited form of EB 
simplex [19]. 
In addition to the simplex forms of EB [20,21], our research 
interests have centered around elucidation of the mutations in the 
dystrophic and junctional forms of EB. As a result of these studies, 
we have identified several mutations in the type VII collagen 
(COL7Al) and the kalinin (Iaminin 5) 12 chain (LAMC2) genes in 
the dystrophic and junctional forms of EB, respectively. 
IDENTIFICATION OF MUTATIONS IN COL7A1 IN 
THE DYSTROPHIC FORMS OF EB 
The early evidence suggesting a role for type VII collagen in the 
pathoetiology of the dystrophic forms of EB (DEB) was based on 
immunofluorescence studies that often demonstrated weak or ab­
sent staining of the cutaneous basement membrane zone with anti­
type VII collagen antibodies [22]. Furthermore, the anchoring fi­
brils, which consist predominantly. if not exclusively. of type VII 
collagen, were shown to be ultrastructurally abnormal, few in num­
ber or entirely absent in DEB [7]. These immunofluorescence and 
ultrastructural observations were subsequently supported by genetic 
linkage analyses that unequivocally established genetic linkage be­
tween the type VII collagen gene (COL7 A1) and the EB locus both 
in dominantly and recessively inherited forms of DEB [23-25]. In 
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Figure 1. Heteroduplex analysis of the DNA segment consisting of 
exoDS 18 and 19 in COL7 Ai in 10 unrelated recessive dystrophic EB 
patients (A). Note a heteroduplex band of slowed mobility in UJne 3 con­
taining a peR product from the proband in the family shown in Fig lA. 
Sequence analysis of the band demonstrating altered mobility in lane 3 re­
vealed a one base pair insertion of a G in exon 19 as shown in B. This 
mutation. 2473insG, leads to a frameshift and premature termination codon 
120 bp downstream of the mutation. (Reproduced with permission from 
[30].) 
fact, among the dominant dystrophic EB (DDEB) and recessive 
dystrophic EB (RDEB) families that have been informative either 
for intragenic or tightly linked genetic markers, no recombinants 
have been detected, suggesting a lack of locus heterogeneity. The 
combined maximum lod score in the 10 DDEB families published 
thus far is Z > 27 at 0 = 0; the corresponding value in 30 RDEB 
families is Z > 7 at 0 = 0 [26]. Thus, it is likely that the majority of 
the DEB cases are due to mutations in COL7A1. 
We have recently completed cloning of the full-length human 
type VII collagen cDNA, and elucidated the intron-exon organiza­
tion of the entire gene [15,27]. This gene was mapped to the short 
arm of chromosome 3 at locus 3p21 [12,23,28]. An unusual feature 
of the gene is that the coding segment, -9.2 kb, consists of a total of 
118 separate exons, more than any other gene published thus far 
[27]. However, the gene is relatively compact, - 32 kb in size, and 
consequently the intron-exon ratio is unusually low, -1.9: 1. 
Premature Termination Codons Underlie the Severe Muti­
Ia�g RDEB Based on sequence information in COL7Al, we 
developed strategies to amplify segments of the gene by polymerase 
chain reaction (PCR). and the amplification products were then 
examined using electrophoretic techniques. such as single strand 
conformation polymorphism (SSCP), denaturing gradient gel elec­
trophoresis (DGGE), or heteroduplex analysis (MDE). These tech­
niques are able to detect single point mutations within PCR prod­
ucts up to several hundred nucleotides in size. Using this strategy, 
we have successfully identified a large number of mutations in one 
or both alleles of patients affected with the severe, mutilating (Hal­
lopeau-Siemens) type of RDEB (HS-RDEB) [29,30]. An example of 
the utilization of this technology is shown in Figs 1 and 2. In this 
case, heteroduplex analysis of a PCR product corresponding to 
exons 18-19 in COL7Al revealed a band of altered mobility, when 
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Figure 2. Heteroduplex analysis the peR product spanning exoDS 18 
and 19 in family members of the proband shown in Pig 1. Note the 
presence of the same shift in the proband's mother (lane 6 inA) and a younger 
brother (lane 10 in A). The muration was confirmed using allele specific 
oligonucleotide (ASO) hybridization, as shown in B. Note the positive 
hybridization to the murant oligomer, confirming the presence of the mura­
tion 2470insG in the proband, his mother and a younger brother. (Repro­
duced with permission from [30].) 
the DNA from a 3S -year old male with severe HS-RDEB was 
examined (Fig lA) [30]. Sequencing of this band revealed a one 
base pair insertion of a G in exon 19 (Fig lB). This mutation, 
designated as 2470insG, leads to a frameshift and premature termi­
nation codon 120 bp downstream in exon20 ofCOL7Al,encoding 
the amino terminal non-collagenous FN III-8A domain. Similar he­
teroduplex and sequence analyses of the PCR product containing 
exon 28-31 sequences of COL7Al revealed a one-base pair dele­
tion of a G in exon 31 in the other allele of the same patient [30]. 
This mutation, designated as 38S 8delG, leads to a frameshift and 
premature termination codon 111 bp downstream of the site of 
mutation in exon 32 of COL 7 A 1, encoding the 5' end of the collag­
enous domain characterized by Gly-X-Y amino acid repeats. Thus, 
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the patient is a compound heterozygote for two different mutations 
in each allele, which leads to a frameshift and premature termina­
tion codon predicting synthesis of truncated al(VII) chain [30]. 
The inheritance of the mutated alleles was verified by heteroduplex 
analysis, restriction endonuclease digestions of genomic DNA, and 
allele specific oligomer (ASO) hybridizations in the members of the 
nuclear family, revealing the paternal and maternal origin of the 
different mutations (Fig 2). 
Utilizing similar strategies, we have thus far identified several 
mutations that result in premature termination codon in patients 
with HS-RDEB (Table I). In the case illustrated above, the patient 
was a compound heterozygote for two separate mutations, whereas 
another patient has been shown to be homozygous for an insertion/ 
deletion (1208dell1/ins2S) in FNIII-4A, resulting in truncation of 
the putative polypeptide within FNIII-SA [29]. In the remaining 12 
cases, the mutation in the other allele has not been disclosed as yet, 
however, we predict that in patients with severe mutilating HS­
RDEB, the other alleles will also contain a premature termination 
codon. The lack of any type VII collagen polypeptides would ex­
plain the absence of anchoring fibrils in these patients, resulting in 
extreme fragility of the skin. 
DEMONSTRATION OF A HOMOZYGOUS MUTATION 
OF THE MITIS TYPE IN RDEB 
The first mutation identified among the recessive dystrophic forms 
of EB was a homozygous missense mutation in the mitis form of 
RDEB [31]. This mutation was anA-tooT transversion resulting in 
the substitution of a methionine residue by a lysine within the 
carboxy-terminal NC-2 domain at amino acid position 2798 
(Table I). The affected individuals were homozygous for the muta­
tion, whereas the heterozygous carriers were clinically normal [31]. 
Of particular interest in this case was that the amino acid substitu­
tion occurred within a 67 -amino acid segment that was precisely 
conserved between hamster and human through evolution, sug­
gesting functional importance [15] . This methionine-to-Iysine sub­
stitution also resides 4 and 6 amino acids upstream from two con­
served cysteine residues that have been postulated to participate in 
the intermolecular disulfide bonding during the assembly of an­
choring fibrils [8]. 
It is of interest to note that in two other patients with the mitis 
form ofRDEB, a premature termination codon has been disclosed in 
Table I. Mutations in the Type VII Collagen Gene (COL7Al) in Different Forms 
of Dystrophic Epidermolysis Bullosa (DEB)" 
Consequence 
HS-RDEB 
2470insG/3858de1G PTC/PTC 
1208de111/ins25 (homozygous) PTC/PTC 
W796X PTC/? 
1172delAT PTC/? 
R1212X PTC/? 
R1215X PTC/? 
R108X PTC/? 
R1344X PTC/? 
497insA PTC/? 
497insA PTC/? 
6522insC PTC/? 
5818delC PTC/? 
Mitis/Inversa RDEB 
M2798K (homozygous) Mis/Mis 
1895delG PTC/? 
R108X PTC/? 
DDEB 
G2040S Glycine 
substitution 
Sourceb 
NEBR Stanford 
INSERM, CreteH 
NEBR Stanford 
NEBR Stanford 
INSERM, CreteH 
INSERM, CreteH 
INSERM, CreteH 
NEBR Rockefeller 
IDI, Rome, Italy 
IDI, Rome, Italy 
NEBR Rockefeller 
Keio University, Japan 
NEBR Rockefeller 
Jefferson, Philadelphia 
INSERM, CreteH 
Kuopio University, 
Finland 
Reference' 
[30] 
[29] 
[30
1 [30 
-* 
-* 
[31) 
[52] 
[32] 
• Abbreviations: HS-RDEB, the Hallopeau-Siemens type of recessive DEB; DDEB, dominant DEB; PTC, premature termination codon; Mis, missense mutation; the question 
mark signifies that the mutation in the second allele has not been disclosed as yet. 
I Referral source of the patients, cultured cells or DNA: NEBR, National EB Registry at the location indicated; IDI, Istituto Dennopatico dell'lmmacolata. 
, The cases with a reference number have been published as indicated; -indicates unpublished cases; the two cases marked by an asterisk were reported in the 1994 Annnal Meeting 
of the Society for Investigative Dermatology (Ciatti S, et a/: ] Invest Dermato/l02:617, 1994, abstract). 
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Figure 3_ Schematic: representation of consequences of mutations in 
the type vn collagen gene, COL7Al. A, in normal individuals the 
COL7A1 alleles encode a1(VII) polypeptides forming triple-helical type 
VII collagen monomers that align into anti-parallel dimer molecules and 
assemble into normal anchoring fibrils. B, premature termination codons (x) 
in COL7 A 1 alleles result in synthesis of truncated polypeptides that resultin 
the severe, Hallopeau-Siemens type of RDEB [29,30). C, a homozygous 
missense mutation (II) within the NC-2 domain has been shown to result in 
the miris type ofRDEB [31], probably due to interference in the association 
of the type VII collagen monomers into disulfide bonded anti-parallel 
dimers. D, a missense mutation (0) resulting in substitution of a glycine 
residue by another amino acid in the triple-helical portion of the type VII 
collagen causes a dominant negative interference in the formation of stable 
homotrlmers [32]. Because one of eight homotrlmer molecules consist of 
three normal a1(VII) chains, the clinical phenotype of dominantly inherited 
dystrophic EB patients is milder than that in recessive dystrophic EB. (Re­
produced with permission from [32).) 
one of their alleles, as shown in Table I. Based on the observations 
on HS-RDEB we predict that the second allele in these cases con­
tains a mutation somewhat similar to the homozygous missense 
mutation noted in the mitis family, thus explaining the milder 
clinical phenotype in general, and the lack of fusion of the fingers in 
particular. 
DEMONSTRATION OF A GLYCINE SUBSTITUTION 
IN THE TRIPLE-HELICAL DOMAIN OF COL7A1 IN 
DOMINANT DYSTROPHIC EB (DDEB) 
As indicated above, at least 10 families with the dominantly inher­
ited form of dystrophic EB thus far have been linked to the type VII 
collagen gene (COL7 A1), without evidence of locus heterogeneity 
[26]. Utilizing the strategy delineated above for detection of muta­
tions in the recessive forms of DEB, we have recently identified a 
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single base substitution underlying DDEB in a large family consist­
ing of 20 affected and 23 unaffected living individuals in four gen­
erations [32]. Most affected individuals demonstrated a clinical phe­
notype consistent with the Cockayne-Touraine type, characterized 
by generalized blistering of the skin with a predilection for the 
extremities. However, some individuals within this family also 
demonstrated features of the Pasini type, which is specifically dis­
tinguished from the Cockayne-Touraine type by the presence of 
albopapuloid lesions [1]. The inheritance of the mutated gene in this 
family was previously linked to the COL7 A110cus on 3p21 (Z = 
6.66 at () = 0) using both intragenic and flanking markers [23,24]. 
Furthermore, diagnostic transmission EM suggested that the num­
ber of anchoring fibrils was reduced, and the fibers were abnormally 
thin [32,33]. 
Amplification of DNA from the affected individuals revealed 
that the PCR product spanning exon 73 of COL7 A1 demonstrated 
a band of altered mobility upon heteroduplex analysis [33]. Se­
quencing of this band revealed the presence of an A in nucleotide 
position 6118 in affected individuals, whereas the unaffected family 
members, as well as 18 unrelated, ethnically matched individuals 
demonstrated the presence of a G [32] . Furthermore, this base sub­
stitution was not present in 73 unrelated patients with different 
forms of dystrophic EB with varying ethnic backgrounds. The co­
segregation of the mutation and the clinical phenotype within this 
family was confirmed with restriction endonuclease digestion of 
genomic DNA using Bfal. These observations suggested that the 
G-to-A transition, designated as G 2041 S and resulting in the substi­
tution of a glycine residue by a serine, is the underlying cause of 
DDEB in this family (Table I) [32]. In support of this notion is the 
observation that the substitution of the glycine residue by a serine 
occurred within a region of the collagenous domain consisting of24 
uninterrupted Gly-X-Y amino acid repeats in the al(VII) polypep­
tide. Previous studies of heritable collagen diseases have disclosed 
over 100 missense mutations that result in the substitution of a 
glycine residue by another amino acid in the genes encoding type I, 
II, III, and IV collagens, and manifesting clinically as osteogenesis 
imperfecta, chondrodystrophies, Ehlers-Danlos syndrome type IV, 
and Alport syndrome, respectively [34,35]. These observations un­
derscore the likelihood that the glycine-to-serine substitution in 
DDEB results in destabilization of the triple-helical domain within 
type VII collagen, leading to functionally abnormal anchoring fi­
brils. 
Demonstration of different types of mutations in the same gene, 
COL 7 A 1, in both dominantly and recessively inherited forms ofEB 
raises the question as to the mechanisms leading to the clinically 
distinct phenotypes. As depicted in Fig 3, the pathogenetic muta­
tions in the severe mutilating, Hallopeau-Siemens type of RDEB 
disclosed thus far are premature termination codons in both alleles, 
leading to formation of truncated polypeptides that are unable to 
assemble into functional anchoring fibrils. In such cases, the an­
choring fibrils are entirely absent and the skin and the mucous 
membranes are extremely fragile, resulting in severe scarring as a 
Table U. New Nomenclature for the Subunit Polypeptide Chains of Laminin, Its Isoforms, and Their Genes 
Protein Designation Chain Designation 
Chain 
Previous New Composition Previous New Gene 
EHS laminin Laminin-l alpl1'l A,Ae al LAMAI 
Merosin Laminin-2 a2pl1'l M,Am a2 LAMA2 
S-laminin Laminin-3 alP21'l 200 kDa' a3 LAMA3 
Merosin/S-laminin Laminin-4 a2P21'l Bl,Ble PI LAMBI 
Kalinin-Nicein Laminin-5 a3fJ3y2 s, Bis P2 LAMB2 
K-laminin Laminin-6b a3pl1'l 140 kDa' P3 LAMB3 
KS-Iaminin Laminin-7b a3P21'l B2, B2e 1'1 LAMCl 
B2t" 1'2 LAMC2 
• Identified in kalininj nicem. 
6 Tbe identity of tbe a cbains in laminins 6 and 7 witb tbe a3 chain gene of Iaminin-5 is not firmly establisbed. 
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Table m. Mutations in the Kalinin B2/Laminin )12 Chain Gene (LAMC2) in the Junctional Forms of Epidermolysis Bullosa· 
Mutation Consequence Source Reference 
1184-1G -4A 
2336del20 /insG 
R95X 
Homozygous exon skip 
Heterozygous deletion/insertion 
Homozygous PTC 
NEBR Rockefeller 
NEBR Rockefeller 
Nice, France 
[45] 
[45] 
[46] 
• For abbreviation and other explanations, see Tables I and D. 
result of minor trauma [26]. It is of interest, however, that the 
heterozygous carriers of one allele containing a premature termina­
tion codon and one allele being normal demonstrate an approxi­
mately 50% reduction in the number of anchoring fibrils, yet their 
skin is clinically normal [30]' This observation has apparent impli­
cations for prospective gene therapy, suggesting that only 50%, or 
perhaps even less, of the normal number of anchoring fibrils need to 
be replaced in order to restore the integrity of the dermal-epidermal 
junction in these patients. In contrast to HS-RDEB, DDEB arises 
via an apparent dominant negative mechanism, such that the prod­
uct of the mutated allele interferes with the product of the normal 
allele (Fig 3). However, because type VII collagen is a homotrimer 
consisting of three identical al (VII) chains, only one of eight colla­
gen molecules synthesized is expected to be normal [36]. This no­
tion is consistent with electron microscopic observations that indi­
viduals with DDEB contain few, although frequently thin, 
anchoring fibrils [7]. Nevertheless, the presence of a few thin an­
choring fibrils, as opposed to the complete absence of anchoring 
fibrils observed in HS-RDEB, would explain the milder phenotype 
in the dominantly inherited forms of DEB. It should also be pointed 
out that there are previous examples of structural proteins in which 
mutations in the same gene can result in a dominant negative phe­
notype or manifest clinically as a recessive trait. These include mis­
sense mutations in the keratin 14 gene that result in both D DEB and 
RDEB [3,4,19]. 
IDENTIFICATION OF MUTATIONS IN THE 
KALlNIN/LAMININ 5 GENES IN JUNCTIONAL EB 
As indicated above, the junctional forms ofEB are characterized by 
tissue separation within the dermal-epidermal basement membrane, 
and the lamina lucida protein niceinjkalinin/laminin 5 was initially 
implicated as the candidate protein, based on immunofluorescence 
analysis [37,38]. This protein was first recognized by a monoclonal 
antibody GB3, designated as BM600, and subsequently renamed as 
nicein [39]. At the same time, a basement membrane zone protein , 
named kalinin, was isolated independently [40]. Immunofluores­
cent and biochemical analyses have clearly established that nicein 
and kalinin polypeptides are identical products of the same genes 
[41]. 
Recent cloning of the cDNAs encoding nicein/kalinin subunit 
polypeptides [42-44] has demonstrated that these molecules have a 
high degree of homology with classic laminin initially isolated from 
a mouse tumor (EHS). The classic laminin was shown to consist of 
three polypeptides, the A, Bl, and B2 chains, and subsequently, 
several isoforms of laminin, including merosin, S-laminin, K-Ia­
minin, and nicein/kalinin have been characterized [5,11]. To sim­
plify the classification of these various laminin isoforms, a new 
nomenclature has recently been proposed (Table ll). According to 
this nomenclature, nicein/kalinin will be referred to as laminin 5, 
and its A, B 1, and B2 chains will be known as laminin a3, 113, and 1'2 
chains [5]. The designations of the corresponding gene loci are 
LAMA3, LAMB3, and LAMC2, respectively (Table ll). 
Recent cloning of laminin )12 chain cDNA has allowed us to 
synthesize oligomer primers for amplification of the corresponding 
mRNA sequences by reverse transcription - polymerase chain reac­
tion (RT -PCR) [45]. The amplified PCR products were then ex­
amined by similar electrophoretic mutation detection techniques, as 
were previously utilized for identification of mutations in COL7 Al 
in DEB (see above). As a result of these studies, we have identified 
distinct mutations in the gene encoding the laminin )12 chain 
(LAMC2) in three patients with the Herlitz type of junctional EB 
(H-JEB) (Table m). The first case was shown to be a homozygous 
point mutation that produced in-frame exon skipping [45]. Specifi­
cally, the proband of the family was a female who had multiple 
erosions and hemorrhagic blisters noted shortly after birth, and the 
clinical presentation was consistent with autosomal recessive junc­
tional EB (Fig 4..4). Examination of RNA isolated from cultured 
fibroblasts by R T - PCR amplification, revealed a markedly short­
ened product in the nucleotide region 1046 to 1537 (Fig 4B). No 
evidence of the normal size band was noted, suggesting that the 
patient was homozygous for the deletion. Direct sequencing of the 
PCR product amplified from mRNA revealed that the shortened 
product resulted from deletion of 219 bp corresponding to nucleo­
tides 1184-1402, and encompassing exon 9 ofLAMC2 (Fig 5). To 
examine whether this deletion in the coding region of the mRNA 
resulted from a change in the genomic DNA, the corresponding 
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49' .... 
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2 
2 3 '" 
peR-ANALYSIS OF JEB PATIENTS 
2 3 4 5 
* 
MW 
Figure 4. Pedigree of ajuDctional EB family OEB1) (A). aDd PCR­
analysis of a panel of 5 unrelated patients with JEB (B). PCR amplifi­
cation of the mRNA segment corresponding to nucleotides 1046-1537 of 
the laminin )12 chain demonstrated a shortened, 273-bp fragment in lane 3, as 
compared to the normal size 491-bp fragment noted in four other patients. 
The molecular weight markers (MW) are shown on the right hand side ofB. 
(Reproduced with permission from [45].) 
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Figure s. Nucleotide sequencing of the mutated cDNA (A) and genomic DNA (B) in the case ofJEBl demonstrating the shortened peR 
amplification product, as shown in Fig 4. By comparison with the normal cDNA sequence, the patient's mRNA is missing the 219-bp segment 
corresponding to nucleotides 1184-1402. Comparison with genomic sequences indicates that this mutation reflects in-frame skipping of ex on 9 in the mRNA 
due to G-to-A transition at the 3' acceptor splice site of intron 8, in a manner that deletes exon 9 from the mRNA, as schematically demonstrated in C. 
(Reproduced with permission from [451.) 
DNA segment was sequenced. Sequencing of the genomic DNA 
revealed the presence of sequences encoding exons 8, 9, and 10. 
However, careful examination of the nucleotide sequence revealed 
a homozygous G-to-A substitution at the 3' acceptor splice site at 
the junction of intron 8 and exon 9, and as a result, the obligatory 
splice site sequence (AG) was abolished (Fig SB). This homozygous 
point mutation resulted in aberrant in-frame splicing of exon 9 from 
the mRNA, and predicted shortening of the laminin )12 chain by 73 
amino acids (Fig SC). Further studies examining RNA from the 
mother's fibroblasts revealed that she was a heterozygous carrier, 
with one affected and one normal allele, without evidence of clini­
cal disease [45]. In addition, 21 unrelated healthy individuals as well 
as 11 unrelated patients with JEB demonstrated the presence of a 
normal G. Thus, the proband of this family is homozygous for the 
mutation, and again, the heterozygous carriers do not demonstrate 
the clinical phenotype [45]. 
In addition to this family, a homozygous point mutation leading 
to a premature stop codon (CGA - TGA) was identified in exon 5 
of LAMC2 in another family with evidence of consanguinity 
(Table m) [46]. Northern analysis of keratinocyte RNA from the 
patient with the homozygous premature termination codon muta­
tion demonstrated the absence of any detectable transcript corre� 
sponding to the laminin )12 chain mRNA [46]. Premature termina­
tion codons have been shown to decrease transcript levels by 80 to 
90% in other genes, probably explaining the absence of hybridiza­
tion in Northern analysis. Finally, a heterozygous deletion-inser­
tion mutation has been identified in one allele of a patient with JEB 
(Table m). This mutation, 2336del20/insG. causes a frameshift 
that also results in a premature stop codon in one allele. predicting a 
truncated _polypeptide terminating at residue 830 [45]. The clini­
cally unaffected father of the proband was heterozygous for this 
mutation, whereas the putative mutation in the other allele of the 
proband's LAMC2 has not been disclosed as yet. 
In addition to these patients in which mutations in LAMC2 have 
been demonstrated. genetic linkage analyses using a highly infor­
mative (CA/GT)n dinucleotide repeat polymorphism have sug­
gested presence of a mutation in LAMC2 in three other families that 
are currently under investigation [46]. It should be noted, however, 
that among the eight families with recessively inherited H-JEB that 
were subjected to linkage analysis, four families were excluded from 
linkage to the LAMC210cus [46]. This result suggests that H-JEB is 
a heterogeneous group of diseases, and the a3 and {J3 chains of 
kalinin/laminin 5, or other genes encoding cutaneous basement 
membrane zone proteins, may harbor mutations resulting in the 
JEB phenotype. This notion is consistent with recent immunofluo­
rescence, genetic linkage, and Northern analysis data on patients 
withJEB l46,47]. 
IMPLICATIONS OF THE MUTATIONS 
Identification of the candidate genes and rrecise delineation of mu­
tations underlying the different fortns 0 EB allow us to begin to 
establish genotype-phenotype correlations in the affected patients. 
As a result of this information, we can now begin to classify, and 
eventually treat, patients on the basis of their molecular defects, 
rather than on often subtle differences in the clinical phenotypes. 
However, the immediate benefit of identifying candidate genes and 
disclosing distinct mutations in these patients relates to the prospect 
of prenatal diagnosis. In fact, DNA-based prenatal diagnosis from 
chorionic villi has already been performed in families at risk for 
recurrence ofRDEB [48]. Thus far, we have correctly predicted the 
clinical phenotype of the fetus in three cases, based on genotype 
analysis of DNA from chorionic villi. obtained as early as the ninth 
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week of gestation. A future extension of prenatal diagnosis is preim­
plantation diagnosis following in vitro fertilization [49]. In this pro­
cedure, the fertilized oocytes are allowed to mature to the eight cell 
blastomere stage, and one of the cells is removed for DNA analysis. 
Removal of one of the cells does not have deleterious consequences 
for the subsequent development of the embryo from seven-cell blas­
tocyst. If blastomeres with two normal alleles or a carrier genorype 
are identified, they can be reimplanted into the recipient mother to 
initiate the pregnancy. Ultimately, understanding the molecular 
basis of different forms ofEB resulting from different combinations 
of mutations in distinct genes, such as mutations in COL7Al and 
LAMC2 in the dystrophic and junctional forms ofEB, respectively, 
will provide the foundation for future application of gene therapy. 
For example, these approaches could consist of stable transfection of 
autologous keratinocytes with the normal type VII collagen gene, 
followed by replantation of the transfected keratinocytes expressing 
the normal gene to a denuded area of the skin [50]. In the future, the 
use of a biolistic particle accelerator could deliver the normal gene 
directly into the stem cell population of the epidermal keratinocytes 
[5 1]. 
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